PRECIGEN, INC. (PGEN)
PRECIGEN, INC. (PGEN) from its SEC filings: 2025 revenue $9.7 million (+147% vs the year before), net margin -2588%, free cash flow -$89.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $9.7 million |
| Revenue growth | +147% |
| Net income | -$250.6 million |
| Net margin | -2587.8% |
| Free cash flow | -$89.8 million |
| Diluted EPS | $-1.37 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +6323% |
| Cash | $16.3 million |
| Long-term debt | $93.9 million |
| Share count, 1 year | +20% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.